UPDATED: Rafael Holdings guts its top leadership, including short-tenured CEO, as cancer fiasco spurs a shakeup
Ameet Mallik left Novartis to claim the CEO spot at Rafael Holdings back in May, taking the reins from founder Howard Jonas. Now — one month after a stock-crushing pivotal failure in pancreatic cancer that sent Rafael’s team back to the drawing board — Mallik is taking off for greener pastures.
Mallik will hand his chief executive responsibilities back to Jonas on Feb. 1 as part of an overhaul that’s set to shake up the highest rungs of the company, Rafael announced Monday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.